Diabetes Drug Increases Heart Attack Risk
The Food and Drug Administration (FDA) issued an alert May 21 after non-FDA affiliated researchers reported that the Type 2 diabetes drug Avandia' (rosiglitazone maleate) has been shown to increase heart attack risk.
This premium content is locked for LawJournalNewsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.